Intra‐individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9activity
- 1 August 2002
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 54 (2), 183-185
- https://doi.org/10.1046/j.1365-2125.2002.01646.x
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotypeClinical Pharmacology & Therapeutics, 2002
- Severe phenytoin intoxication in a subject homozygous forCYP2C93Clinical Pharmacology & Therapeutics, 2001
- Severe phenytoin intoxication in a subject homozygous for CYP2C9*3Clinical Pharmacology & Therapeutics, 2001
- Role of CYP2C9 polymorphism in losartan oxidation.2001
- Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probesPharmacogenetics, 2000
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allelePharmacogenetics, 1999
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.1995